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Abstract
Background: Breast cancer (BC) is the most common female cancer and the leading cause of cancer death in
women worldwide. Alterations in epithelial cadherin (E-cadherin) expression and functions are associated to BC, but
the underlying molecular mechanisms have not been fully elucidated. We have previously reported a novel human
E-cadherin splice variant (E-cadherin variant) mRNA. Stable transfectants in MCF-7 human BC cells (MCF7Ecadvar)
depicted fibroblast-like cell morphology, E-cadherin wild-type downregulation, and other molecular changes
characteristic of the epithelial-to-mesenchymal transition process, reduced cell-cell adhesion, and increased cell
migration and invasion. In this study, a two-dimensional differential gel electrophoresis (2D-DIGE) combined with
mass spectrometry (MS) protein identification and bioinformatics analyses were done to characterize biological
processes and canonical pathways affected by E-cadherin variant expression.
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Results: By 2D-DIGE and MS analysis, 50 proteins were found differentially expressed (≥Δ1.5) in MCF7Ecadvar
compared to control cells. Validation of transcript expression was done in the ten most overexpressed and
underexpressed proteins. Bioinformatics analyses revealed that 39 of the 50 proteins identified had been previously
associated to BC. Moreover, metabolic processes were the most affected, and glycolysis the canonical pathway most
altered. The lactate dehydrogenase B (LDHB) was the highest overexpressed protein, and transcript levels were higher
in MCF7Ecadvar than in control cells. In agreement with these findings, MCF7Ecadvar conditioned media had lower
glucose and higher lactate levels than control cells. MCF7Ecadvar cell treatment with 5 mM of the glycolytic inhibitor
2-deoxy-glucose led to decreased cell viability, and modulation of LDHB expression in MCF7Ecadvar cells with a
specific small interfering RNA resulted in decreased cell proliferation. Finally, a positive association between expression
levels of the E-cadherin variant and LDHB transcripts was demonstrated in 21 human breast tumor tissues, and breast
tumor samples with higher Ki67 expression showed higher LDHB mRNA levels.
Conclusions: Results from this investigation contributed to further characterize molecular changes associated to the
novel E-cadherin splice variant expression in BC cells. They also revealed an association between expression of the
novel variant and changes related to BC progression and aggressiveness, in particular those associated to cell metabolism.
Keywords: Breast cancer, Epithelial cadherin, Alternative splicing, Epithelial to mesenchymal transition, Proteomic analysis,
2D-DIGE, Mass spectrometry, Glycolysis, Lactate dehydrogenase B
Background
Breast cancer (BC) is the most common cancer in
women, representing 25% of female cancers. More-
over, it is the fifth cause of cancer death and women
death leading cause by cancer [1]. Taking into ac-
count the high incidence and mortality associated to
BC, it is still a great challenge to delve into the mo-
lecular mechanisms involved in the origin and pro-
gression of this heterogeneous disease, to better
understand its pathogenesis and to identify novel bio-
markers and new therapeutic targets.
Epithelial cadherin (E-cadherin) is a calcium-ion
dependent cell-cell adhesion molecule that plays a key
role in the maintenance of normal epithelia intercellular
junctions and in a variety of processes fundamental to
tissue homeostasis, such as differentiation, proliferation,
migration, cell death, and survival [2]. A partial or total
loss of E-cadherin expression and/or function(s) has
been reported in numerous tumors of epithelial origin,
among them in breast tumors, leading to destabilization
of cell-cell interactions and aberrant activation of cellu-
lar signaling pathways [3, 4]. A reduced expression of
E-cadherin is a hallmark of epithelial-mesenchymal tran-
sition (EMT), a process that induces changes in gene ex-
pression and in cell behavior that have been associated
with tumor progression and aggressiveness [5]. Despite
its relevance, the underlying molecular alterations lead-
ing to deregulation of E-cadherin expression and func-
tion(s) have not been completely characterized. Among
the most frequent mechanisms responsible of these
changes are a loss of heterozygosity, mutations, epigen-
etic silencing, expression of transcriptional repressors,
and post-translational modifications [6, 7]. In recent
years, a differential regulation of alternative splicing (AS)
and its association with molecular and phenotypic
changes has been reported during EMT [8, 9]. Under
normal conditions, AS regulates gene expression and
contributes to the expansion of proteomic diversity in a
spatially and temporally controlled fashion. However,
during malignant transformation, AS events have been
reported in tumor suppressor genes or oncogenes, which
result in association with mutations at specific splice
sites and/or with changes in the expression of AS regula-
tory factors, among other causes, changes that contrib-
ute to tumor progression and the acquisition of
therapeutic resistance [10, 11].
We have recently reported, for the first time, a novel
transcript of human E-cadherin that differs from the
wild-type E-cadherin (E-cadherin wt) mRNA by lacking
the first 34 bp of Exon 14. This novel variant, called
E-cadherin variant, would result from an AS event of the
immature E-cadherin mRNA. Its expression levels would
be regulated, at least in part, by the nonsense-mediated
mRNA decay (NMD) surveillance mechanism. The
E-cadherin variant mRNA was detected in cell lines de-
rived from different human tumors types. Moreover,
stable transfection of the E-cadherin variant in the
MCF-7 human BC cell line (MCF7Ecadvar) induces a
significant decrease in the E-cadherin wt (transcript and
protein) expression, as well as changes that resemble the
EMT process. MCF7Ecadvar cells depict a fibroblast-like
morphology, and show changes in the expression levels
of several EMT markers (i.e. cytokeratins, vimentin, and
neural cadherin), reduced cell-cell interaction, increased
cell migration and cell invasive properties when com-
pared to the control cell line [12].
The present study aimed to thoroughly characterize
molecular changes associated to the novel E-cadherin
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splice variant mRNA expression in MCF-7 cells, by per-
forming a proteomic analysis using the two-dimensional
differential gel electrophoresis (2D-DIGE) technology
combined with protein identification by mass spectrom-
etry (MS). In addition, this study aimed to identify other
cellular processes and cell signaling pathways affected by
the expression of the novel E-cadherin splice variant
mRNA using bioinformatics tools, and to compare these
changes with those previously associated with BC. Fi-
nally, studies on the lactate dehydrogenase B chain
(LDHB) enzyme were done; this protein was identified
in the proteomic analysis with the highest increased ex-
pression in MCF7Ecadvar compared to MCF7pcDNA3
control cells.
Results
2D-DIGE and MS proteomic analysis of MCF7Ecadvar cells
To assess the global protein profile of MCF-7 cells stably
transfected with the novel E-cadherin variant transcript,
an expression analysis was carried out using the
2D-DIGE technique coupled to protein identification by
MS. For this purpose, MCF7Ecadvar and MCF7pcDNA3
cell cultures (three per cell line) were prepared and
processed by means of total protein precipitation and
quantification, as detailed in “Materials and Methods”
section. Downregulation of E-cadherin wt in MCF7Ecad-
var cells was confirmed by Western immunoblotting of
total protein extracts (Additional file 1: Figure S1).
Total protein extracts from MCF7pcDNA3 and
MCF7Ecadvar cells were then labeled with fluorescent
dyes, mixed, and separated by isoelectric focusing (first--
dimension) followed by denaturing polyacrylamide gel
electrophoresis (second-dimension). After gel scanning,
protein alignment, and analysis, 64 protein spots were
identified as differentially expressed between both cell
lines (1.5-fold change cutoff and an analysis of variance
(ANOVA) ≤ 0.005). Of these spots, 60 were recovered
and their spectra were obtained by MS. The identity of
each protein spot was determined using the Mascot
Database Search Program (Matrix Science, London, UK).
As result of these studies, 50 proteins were identified:
ten proteins were found overexpressed and 40 underex-
pressed in MCF7Ecadvar cells relative to MCF7pcDNA3
cells. The name and symbol of these proteins, their Uni-
Prot number, the symbol of the gene encoding each pro-
tein, a brief protein functional description, and the fold
change value associated to each protein are included in
Table 1.
Biological characterization of the proteomic analysis
results
To analyze biological characteristics of the 50 differen-
tially expressed proteins found in MCF7Ecadvar cells, a
set of bioinformatics tools were applied. Firstly, proteins
were classified using the Protein ANalysis THrough Evo-
lutionary Relationships (PANTHER) tool, by means of
their molecular function (Fig. 1a) and the biological pro-
cesses (Fig. 1b) in which they were involved. As result,
catalytic activity was the most represented molecular
function (56.0%; 27/50 proteins). Other categories listed
were binding, structural molecule, antioxidant activity,
transporter, and translation regulator. The energy me-
tabolism was identified as the most affected biological
process (34.5%), followed by cellular process (32.2%).
Additional evaluations with the PANTHER tool in-
cluded cellular component and protein class analysis; re-
sults are listed in Additional file 2: Figure S2. With
regard to the cellular component classification, the cell
part category represented a 52.5% (23/50). Among the
protein class categories, 21 (SODC, PRDX2, ALDR,
LDHB, 6PGL, G6PD, ECI1, MAOX, PRDX6, CATD,
EF2, PSB3, PSA6, F16P1, ACPH, PMM2, TPIS, HPRT,
G6PI, GDIB, and UBA1) of the 50 differentially
expressed proteins in MCF7Ecadvar cells were included
in the six enzymatic categories listed in the protein class
classification.
The ingenuity pathway analysis (IPA) bioinformatics
tool was run to evaluate the ten canonical pathways
most affected in the MCF7Ecadvar cellular model; re-
sults were in agreement with the PANTHER analysis
(Table 2).
In particular, the most altered pathways listed in IPA
were glycolysis and gluconeogenesis, two metabolic pro-
cesses composed by a set of consecutive enzymatic reac-
tions. The pentose phosphate metabolic pathway, an
alternative branch of glycolysis to produce sugars that
make up DNA and RNA, was also listed in the seventh
position. In third position, the protein ubiquitination path-
way was found, involving 8/50 proteins identified in the
MCF7Ecadvar cell model. This pathway regulates degrad-
ation of cellular proteins by the ubiquitin-proteasome sys-
tem, controlling protein’s half-life and expression levels as
well as key cellular processes [13]. The p70S6 kinase
(p70S6K) signaling pathway (fifth position) is an import-
ant regulator of the cell cycle, which activation requires
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/
RAC-alpha serine/threonine-protein kinase (AKT)-depen-
dent signal(s), a pathway found in sixth position [14]. Fur-
thermore, key cellular functions are regulated by the other
four canonical pathways identified by the IPA tool, such as
cell growth (pathways number 4 and 10), ion transport
(pathways number 4 and 8), inflammation, immunity, and
metabolism (pathways number 4, 9, and 10) [15–19].
Using IPA, four networks were generated with the 50
proteins differentially expressed in the MCF7Ecadvar cell
line. The score associated to each network, the number
of molecules among the 50 identified by 2D-DIGE and
MS that were part of them (in bold in the
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Table 1 Proteins identified as differentially expressed between MCF7Ecadvar and MCF7pcDNA3 cells
Protein name Protein
symbol
UniProt
number
Gene
symbol
Protein function Fold
L-lactate dehydrogenase B chain LDHB P07195 LDHB Catalysis of the interconversion of pyruvate and lactate with
concomitant interconversion of NADH and NAD+ in a post-
glycolysis process.
9.34
Aldose reductase ALDR P15121 AKR1B1 Catalysis of the NADPH-dependent reduction of a wide var-
iety of carbonyl-containing compounds to their correspond-
ing alcohols with a broad range of catalytic efficiencies.
4.49
Elongation factor 2 EF2 P13639 EEF2 Catalysis of the GTP-dependent ribosomal translocation step
during translation elongation. Catalysis of the coordinated
movement of the two tRNA molecules, the mRNA and con-
formational changes in the ribosome.
3.94
Heat shock protein HSP 90-beta HS90B P08238 HSP90AB1 Molecular chaperone. Promotion of the maturation, structural
maintenance, and regulation of specific target proteins
involved in cell cycle control and signal transduction. ATPase
activity. Regulation of the transcription machinery at different
levels: alteration of certain transcription factors levels in
response to physiological cues, modulation of certain
epigenetic modifiers, and participation in the eviction of
histones from the promoter region of specific genes to turn
on gene expression.
3.42
14-3-3 protein theta 1433 T P27348 YWHAQ Adapter protein. Regulation of a large spectrum of both
general and specialized signaling pathways. Binding to a large
number of partners, usually by recognition of a
phosphoserine or phosphothreonine motif, which results in
the modulation of the binding partner activity.
3.36
Vimentin VIME P08670 VIM Class-III intermediate filament found in diverse non-epithelial
cells, especially mesenchymal cells. Attached to the nucleus,
endoplasmic reticulum and mitochondria, either laterally or
terminally.
3.05
Ubiquitin-like modifier-activating
enzyme 1
UBA1 P22314 UBA1 Catalysis of the first step in ubiquitin conjugation to mark
cellular proteins for degradation through the ubiquitin-
proteasome system. Essential for the formation of radiation-
induced foci, timely DNA repair and response to replication
stress.
2.66
Protein disulfide-isomerase A3 PDIA3 P30101 PDIA3 Prevention of the formation of protein aggregates. Catalysis
of the rearrangement of -S-S- bonds in proteins. Complexes
of lectins and this protein mediate protein folding by
promoting formation of disulfide bonds in their glycoprotein
substrates.
2.14
Prelamin-A/C LMNA P02545 LMNA Component of the nuclear lamina, a fibrous layer on the
nucleoplasmic side of the inner nuclear membrane, which
provides a framework for the nuclear envelope. The structural
integrity of the lamina is strictly controlled by the cell cycle.
Lamin A and C are present in equal amounts in the lamina of
mammals. Role in nuclear assembly, chromatin organization,
nuclear membrane, and telomere dynamics.
2.00
Protein disulfide-isomerase A6 PDIA6 Q15084 PDIA6 Inhibition of misfolded proteins aggregation. Catalysis of the
rearrangement of -S-S- bonds in proteins.
1.87
Downregulated
Cellular retinoic acid-binding protein 2 RABP2 P`29373 CRABP2 Transportation of retinoic acid to the nucleus. Regulation of
the access of retinoic acid to the nuclear retinoic acid
receptors.
− 10.97
14-3-3 protein zeta/delta 1433Z P63104 YWHAZ Idem 14-3-3 protein theta. − 5.21
Triosephosphate isomerase TPIS P60174 TPI1 Role in the gluconeogenesis pathway. Participation in step 1
of the subpathway that synthesizes D-glyceraldehyde 3-
phosphate from glycerone phosphate.
− 4.60
Glucose-6-phosphate
1-dehydrogenase
G6PD P11413 G6PD Catalysis of the rate-limiting step of the oxidative pentose-
phosphate pathway, a route for the dissimilation of carbohy-
drates besides glycolysis. Provision of reducing power
(NADPH) and pentose phosphates for fatty acid/nucleic acid
− 4.54
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Table 1 Proteins identified as differentially expressed between MCF7Ecadvar and MCF7pcDNA3 cells (Continued)
Protein name Protein
symbol
UniProt
number
Gene
symbol
Protein function Fold
synthesis.
Heat shock protein HSP 90-alpha HS90A P07900 HSP90AA1 Idem Heat shock protein HSP 90-beta. − 4.32
Gamma-glutamylcyclo transferase GGCT O75223 GGCT Catalysis of the formation of 5-oxoproline from gamma-
glutamyl dipeptides. Role in glutathione homeostasis. Induc-
tion of the release of cytochrome c from mitochondria with
resultant induction of apoptosis.
− 4.20
Peroxiredoxin-2 PRDX2 P32119 PRDX2 Thiol-specific peroxidase. Catalysis of the reduction of
hydrogen peroxide and organic hydroperoxides to water and
alcohols, respectively. Role in cell protection against oxidative
stress by detoxifying peroxides and as a sensor of hydrogen
peroxide-mediated signaling events. Participation in the sig-
naling cascades of growth factors and tumor necrosis factor-
alpha by regulating the intracellular concentrations of H2O2.
− 4.20
Cathepsin D CATD P07339 CTSD Acid protease active in intracellular protein breakdown. Role
in APP processing following cleavage and activation by
ADAM30, which leads to APP degradation.
− 3.57
Annexin A4 ANXA4 P09525 ANXA4 Calcium/phospholipid-binding protein which promotes
membrane fusion and is involved in exocytosis.
− 3.56
Protein S100-A11 S10AB P31949 S100A11 Promotion of keratinocytes differentiation and cornification. − 3.06
Fructose-1,6-bisphosphatase 1 F16P1 P09467 FBP1 Hydrolysis of fructose 1,6-bisphosphate to fructose 6-
phosphate in the presence of divalent cations. Rate-limiting
enzyme in gluconeogenesis. Regulation of glucose sensing
and insulin secretion of pancreatic beta-cells. Modulation of
glycerol gluconeogenesis in liver. Regulator of appetite and
adiposity.
− 3.00
Adenine phosphoribosyl transferase APT P07741 APRT Catalysis of a salvage reaction resulting in the formation of
AMP, that is energically less costly than de novo synthesis.
Involved in step 1 of the subpathway that synthesizes AMP
from adenine.
− 2.71
Transitional endoplasmic reticulum
ATPase
TERA P55072 VCP Participation in the fragmentation of Golgi stacks during
mitosis and in their reassembly after mitosis. Role in the
endoplasmic reticulum (ER) stress-induced pre-emptive qual-
ity control, which attenuates the translocation of newly syn-
thesized proteins into the ER and reroutes them to the
cytosol for proteasomal degradation. Participation in DNA
damage response. Role in the maturation of ubiquitin-
containing autophagosomes and the clearance of ubiquiti-
nated protein by autophagy.
− 2.62
Enoyl-CoA delta isomerase 1,
mitochondrial
ECI1 P42126 ECI1 Isomerization of 3-cis and trans double bonds into the 2-trans
form in a range of enoyl-CoA species. Participation in the fatty
acid beta-oxidation pathway, which is part of lipid
metabolism.
− 2.54
Actin, cytoplasmic 1 ACTB P60709 ACTB Role in various types of cell motility. Ubiquitously expressed
in all eukaryotic cells. There are three main groups of actin
isoforms in vertebrates. The alpha actins are found in muscle
tissues and are a major constituent of the contractile
apparatus. The beta and gamma actins coexist in most cell
types as components of the cytoskeleton and as mediators of
internal cell motility.
− 2.20
Nucleoside diphosphate kinase B NDKB P22392 NME2 Role in the synthesis of nucleoside triphosphates other than
ATP. Negative regulation of Rho activity. Transcriptional
activator of the MYC gene. Binding of DNA in a non-
specifically way. Histidine protein kinase activity.
− 2.11
Chloride intracellular channel protein 1 CLIC1 O00299 CLIC1 Capacity of insertion into membranes and formation of
chloride ion channels. Membrane insertion seems to be
redox-regulated and may occur only under oxydizing condi-
tions. Channel activity depends on the pH. Participation in cell
cycle regulation.
− 2.00
Heterogeneous nuclear HNRH1 P31943 HNRNPH1 Component of the heterogeneous nuclear ribonucleoprotein − 1.94
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Table 1 Proteins identified as differentially expressed between MCF7Ecadvar and MCF7pcDNA3 cells (Continued)
Protein name Protein
symbol
UniProt
number
Gene
symbol
Protein function Fold
ribonucleoprotein H (hnRNP) complexes which provide the substrate for the
processing events that pre-mRNAs undergo before becoming
functional, translatable mRNAs in the cytoplasm. Regulation
of pre-mRNA alternative splicing.
Growth factor receptor-bound protein
2
GRB2 P62993 GRB2 Adapter protein that provides a critical link between cell
surface growth factor receptors and the Ras signaling
pathway.
− 1.94
Superoxide dismutase [Cu-Zn] SODC P00441 SOD1 Destruction of radicals which are normally produced within
the cells and are toxic to biological systems. Zinc binding
promotes dimerization and stabilizes the native form of the
protein.
− 1.85
Glucose-6-phosphate isomerase G6PI P06744 GPI Glycolytic enzyme. Participation in step 2 of the subpathway
that synthesizes D-glyceraldehyde 3-phosphate and glycerone
phosphate from D-glucose. Mammalian GPI can also function
as a tumor-secreted cytokine and an angiogenic factor that
stimulates endothelial cell motility.
−1.84
Proteasome subunit alpha type-6 PSA6 P60900 PSMA6 Component of the 20S core proteasome complex involved in
the proteolytic degradation of most intracellular proteins.
Associated with two 19S regulatory particles, forms the 26S
proteasome and participates in the ATP-dependent degrad-
ation of ubiquitinated proteins. The 26S proteasome plays a
role in the maintenance of protein homeostasis by removing
misfolded or damaged proteins that could impair cellular
functions, as well as proteins whose functions are no longer
required.
− 1.82
Phosphoma nnomutase 2 PMM2 O15305 PMM2 Participation in the synthesis of the GDP-mannose and
dolichol-phosphate-mannose required for a number of critical
mannosyl transfer reactions.
− 1.82
Phospho glycerate mutase 1 PGAM1 P18669 PGAM1 Interconversion of 3- and 2-phosphoglycerate with 2,3-
bisphosphoglycerate as the primer of the reaction.
− 1.82
Glycerol-3-phosphate dehydrogenase,
mitochondrial
GPDM P43304 GPD2 Participation in step 1 of the subpathway that synthesizes
glycerone phosphate from sn-glycerol 3-phosphate (anaer-
obic route). Calcium-binding enhance its activity.
− 1.77
Heat shock 70 kDa protein 1A HS71A P0DMV8 HSPA1A Molecular chaperone. Participation in protection of the
proteome from stress, folding and transport of newly
synthesized polypeptides, activation of proteolysis of
misfolded proteins, and formation and dissociation of protein
complexes. ATPase activity. Regulation of centrosome
integrity during mitosis. Negative regulation of the heat
shock-induced HSF1 transcriptional activity during the attenu-
ation and recovery phase period of the heat shock response.
− 1.77
Heat shock 70 kDa protein 1B HS71B P0DMV9 HSPA1B Molecular chaperone. Participation in protection of the
proteome from stress, folding and transport of newly
synthesized polypeptides, activation of proteolysis of
misfolded proteins, and formation and dissociation of protein
complexes. ATPase activity. Regulation of centrosome
integrity during mitosis.
− 1.77
NADP-dependent malic enzyme MAOX P48163 ME1 Catalysis of the reversible oxidative decarboxylation of malate.
Generation of NADPH for fatty acid biosynthesis. Link
between the glycolytic and citric acid cycles.
− 1.77
6-phosphogluconolactonase 6PGL O95336 PGLS Hydrolysis of 6-phosphogluconolactone to 6-
phosphogluconate. Participation in step 2 of the subpathway
that synthesizes D-ribulose 5-phosphate from D-glucose 6-
phosphate (oxidative stage of the pentose phosphate
pathway).
− 1.77
Endoplasmic reticulum resident
protein 29
ERP29 P30040 ERP29 Role in the processing of secretory proteins within the ER,
possibly by participating in the folding of proteins.
− 1.76
Fructose-bisphosphate aldolase A ALDOA P04075 ALDOA Role in glycolysis and gluconeogenesis. It may also function
as scaffolding protein. In vertebrates, three forms of this
ubiquitous glycolytic enzyme are found: aldolase A in muscle,
− 1.76
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second column), and the main diseases and functions as-
sociated to each of them are detailed in Table 3.
Among the diseases associated to one of the two net-
works described with the highest score (network number
2) was the term “Cancer.” On the other hand, networks
3 and 4 were related with cellular processes usually al-
tered during tumorigenesis. A graphical representation
of each network was also generated with IPA and shown
in Fig. 2, in which the type of connection between mole-
cules and their function is indicated.
Association between proteomic analysis results and BC
disease
In order to determine whether the proteins identified as
differentially expressed in MCF7Ecadvar cells have
already been reported to be associated with BC, the Dis-
GeNET bioinformatics tool was used. A comprehensive
study was conducted, in which all databases available in
DisGeNET (curated, predicted, and literature) were con-
sidered to search for all the genes associated with terms
that include the words “Breast” or “Mammary”: “Carcin-
oma,” “Cancer,” “Neoplasms,” or “Tumorigenesis”. In
total, 36 terms were identified (March 24, 2018) and,
from the gene lists associated with each of these terms, a
list of 5261 genes (Additional file 3: Figure S3) was gen-
erated using the Venny 2.1.0 interactive tool. A total of
39 from the 50 identified genes had already been re-
ported associated with these terms. Using the DisGeNET
tool, it was also found that for ten of the 11 genes not
previously related to the 36 analyzed terms, an altered
expression had been reported in other carcinomas
(Table 4).
Finally, the PSMB3 gene was not found in the DisGe-
NET database, but a manual search performed in
Table 1 Proteins identified as differentially expressed between MCF7Ecadvar and MCF7pcDNA3 cells (Continued)
Protein name Protein
symbol
UniProt
number
Gene
symbol
Protein function Fold
aldolase B in liver, and aldolase C in brain.
Proteasome subunit beta type-3 PSB3 P49720 PSMB3 Idem Proteasome subunit alpha type-6. − 1.75
Stress-70 protein, mitochondrial GRP75 P38646 HSPA9 Chaperone. Role in mitochondrial iron-sulfur cluster (ISC) bio-
genesis. Regulation of erythropoiesis via stabilization of ISC as-
sembly. It may play a role in the control of cell proliferation
and cellular aging.
− 1.72
Peroxiredoxin-6 PRDX6 P30041 PRDX6 Thiol-specific peroxidase that catalyzes the reduction of
hydrogen peroxide and organic hydroperoxides to water and
alcohols, respectively. It also has phospholipase activity and
can reduce short-chain organic, fatty acid, and phospholipid
hydroperoxides. Role in cell protection against oxidative stress
by detoxifying peroxides and in phospholipid homeostasis.
− 1.70
Heterogeneous nuclear ribonucleo
protein F
HNRPF P52597 HNRNPF Component of the heterogeneous nuclear ribonucleoprotein
(hnRNP) complexes which provide the substrate for the
processing events that pre-mRNAs undergo before becoming
functional, translatable mRNAs in the cytoplasm. Regulation
of alternative splicing events. It binds G-rich sequences in pre-
mRNAs and keeps target RNA in an unfolded state.
− 1.70
Actin, aortic smooth muscle ACTA P62736 ACTA2 Idem Actin, cytoplasmic 1. − 1.70
Echinoderm microtubule-associated
protein-like 2
EMAL2 O95834 EML2 Tubulin binding protein. Inhibition of microtubule nucleation
and growth, resulting in shorter microtubules.
− 1.61
Acylamino-acid-releasing enzyme ACPH P13798 APEH Catalysis of the hydrolysis of the N-terminal peptide bond of
an N-acetylated peptide to generate an N-acetylated amino
acid and a peptide with a free N-terminus. Preferentially cleav-
age of Ac-Ala, Ac-Met and Ac-Ser.
− 1.57
Rab GDP dissociation inhibitor beta GDIB P50395 GDI2 Regulation of the GDP/GTP exchange reaction of most Rab
proteins by inhibiting the dissociation of GDP from them, and
the subsequent binding of GTP to them.
− 1.51
Hypoxanthine-guanine
phosphoribosyl transferase
HPRT P00492 HPRT1 Conversion of guanine to guanosine monophosphate, and
hypoxanthine to inosine monophosphate. Transference of the
5-phosphoribosyl group from 5-
phosphoribosylpyrophosphate onto the purine. Role in the
generation of purine nucleotides through the purine salvage
pathway.
− 1.51
List of the 50 proteins for which changes in the expression levels were found in MCF7Ecadvar cells relative to MCF7pcDNA3 using the 2D-DIGE and MS
technologies. Proteins were listed in a descending order according to their fold change value (1.5-fold change cutoff, ANOVA ≤ 0.005). The protein name and
symbol, the Uniprot number, the symbol of the gene that encodes each protein, and a brief description of the protein function are also included in the table.
NADPH nicotinamide adenine dinucleotide phosphate, GTP guanosine triphosphate, tRNA transfer RNA, GDP guanosine diphosphate, G-rich guanine-rich, N- amino,
Ac- N-protected amino acids, Ala alanine, Met methionine, Ser serine
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Fig. 1 (See legend on next page.)
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PubMed led to the identification of one scientific paper
that related PSMB3 with BC [20], and two reports with
colorectal cancer and multiple myeloma [21, 22].
Validation studies of 2-DIGE and MS proteomic analysis
results
Validation of the results obtained by the 2D-DIGE and
MS technologies was done at the mRNA level, by quan-
titative real-time PCR. Specific primers were designed
for the genes encoding the top 10 up- and downregu-
lated proteins in MCF7Ecadvar cells relative to
MCF7pcDNA3 (Additional file 4: Figure S4). Among the
ten upregulated proteins, the same trend to an increased
expression found at the protein level was determined for
LDHB, AKR1B1, VIM, PDIA3, and LMNA transcripts in
MCF7Ecadvar cells compared with MCF7pcDNA3
(Fig. 3a). On the other hand, no significant differences
were observed in the expression levels of the EEF2,
HSP90AB1, YWHAQ, and PDIA6 mRNAs between both
cell lines (Fig. 3b). For the UBA1 protein-coding tran-
script, a significant decreased expression (p < 0.05) was
registered in MCF7Ecadvar cells relative to the control
cell line, contrasting with the increased protein level
found by proteomics (Fig. 3c). Among the top 10 down-
regulated proteins, a decreased mRNA expression was
also found in CRABP2, YWHAZ, G6PD, HSP90AA1,
CTSD, and ANXA4 (Fig. 4a), while TPI1, PRDX2, and
S100A11 transcript levels did not show significant differ-
ences between MCF7Ecadvar and MCF7pcDNA3 cells
(Fig. 4b). Finally, an increased expression of the GGCT
mRNA was found in MCF7Ecadvar cells compared to
the control, results that contrasted with the decreased
protein expression levels registered in the proteomic
analysis (Fig. 4c).
LDHB expression analysis
Among the 50 proteins identified as differentially
expressed in MCF7Ecadvar cells, the LDHB enzyme
showed the highest level of increase (Fold = 9.34;
Table 1). LDHB is a cytoplasmic protein that catalyzes
the interconversion of pyruvate and lactate, with the
concomitant interconversion of nicotinamide adenine di-
nucleotide (reduced form; NADH) and nicotinamide ad-
enine dinucleotide (oxidized form; NAD+). Previous
reports have associated changes in LDHB expression
with tumor progression. However, while decreased
LDHB levels were reported in prostate, bladder, and he-
patocellular carcinomas [23–25], an increased LDHB ex-
pression was described in lung and pancreatic
adenocarcinomas, non-small-cell lung cancer and
(See figure on previous page.)
Fig. 1 Molecular functions and biological processes associated with the 50 proteins identified. Results obtained with PANTHER. a Column graph
bar in which the percentage (%) of representation of each molecular function was determined from the number of proteins included in each category
(catalytic activity 56.0%, binding 22.0%, structural molecule activity 10.0%, antioxidant activity 6.0%, transporter activity 4.0%, and translation regulator
activity 2.0%). A table including the number and symbol of the proteins involved in each molecular function is also shown. b Column graph bar in
which the percentage (%) of representation of each biological process was determined from the number of proteins included in each category
(metabolic process 34.5%, cellular process 32.2%, response to stimulus 11.5%, localization 9.2%, cell component organization or biogenesis 4.6%,
biological regulation 3.4%, developmental process 3.4%, and multicellular organism process 1.2%). A table including the number and symbol of the
proteins involved in each biological process is also shown
Table 2 Ingenuity canonical pathways associated with the proteins identified as differentially expressed between MCF7Ecadvar and
MCF7pcDNA3 cells. Results obtained with the IPA tool
Ingenuity canonical pathways -log(p value) Proteins involved
Glycolysis 0.0836 G6PI, TPIS, PGAM1, F16P1, ALDOA
Gluconeogenesis 0.0827 G6PI, PGAM1, F16P1, ALDOA, MAOX
Protein ubiquitination pathway 0.0535 PSB3, PSA6, HS90B, GRP75, HS71A, HS71B, HS90A, UBA1
14–3-3-mediated signaling 0.0486 1433 T, GRB2, PDIA3, 1433Z, VIME
p70S6K signaling 0.0483 1433 T, GRB2, PDIA3, EF2, 1433Z
PI3K/AKT signaling 0.0478 1433 T, HS90B, GRB2, 1433Z, HS90A
Pentose phosphate pathway (oxidative branch) 0.0439 6PGL, G6PD
Aldosterone signaling in epithelial cells 0.0431 HS90B, PDIA3, GRP75, HS71A, HS71B, HS90A
PPARα/RXRα activation 0.0413 HS90B, GRB2, GPDM, PDIA3, HS90A
Glucocorticoid receptor signaling 0.0410 HS90B, GRB2, ACTB, GRP75, HS71A, HS71B, HS90A
List of the ten canonical pathways most altered in MCF7Ecadvar cells compared with MCF7pcDNA3. They were ordered in a descending form according to the
number of the negative of the logarithm of the p value assigned to each of them. The symbol of the proteins identified with differential expression levels
between both cell lines that were involved in each pathway are also indicated in the table. PPARα peroxisome proliferator-activated receiver α, RXRα retinoid X
receiver α
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osteosarcoma [26–29]. In BC, its expression has been re-
ported in different cell lines and in human tumors [30,
31].
Immunodetection of the LDHB protein by Western
immunoblotting revealed, under the conditions evalu-
ated, no detectable levels of the enzyme in total protein
extracts of MCF7pcDNA3 cells, whereas a 35 kDa signal
was observed for the MCF7Ecadvar cell line (Fig. 5a). By
immunofluorescence microscopy, a specific signal local-
ized at the cytoplasm of MCF7pcDNA3 and MCF7Ecad-
var cells was detected, which was 3.45 times higher in
MCF7Ecadvar than in control cells (Fig. 5b).
Different types of cancers, including BC, show high
rates of glucose consumption associated with lactate
production, even in the presence of normal levels of oxy-
gen, a phenomenon known as aerobic glycolysis or War-
burg effect [32, 33]. When glucose concentration (mg/
dL) was measured in the conditioned media of MCF7E-
cadvar and MCF7pcDNA3 cell lines, a significant de-
crease (p < 0.05) was observed in the former relative to
the control (Fig. 5c). The assessment of the lactate con-
centration revealed higher levels (p < 0.05) of this metab-
olite in the conditioned medium of MCF7Ecadvar cells
than in the control cell medium (Fig. 5d). In agreement
with these findings, a significant increase (p < 0.05) in
the expression of the monocarboxylate transporters 1
(MCT1) and 4 (MCT4) transcripts was determined in
MCF7Ecadvar cells compared with MCF7pcDNA3
(Additional file 5: Figure S5).
In order to evaluate whether the metabolic differences
observed between MCF7Ecadvar and MCF7pcDNA3 cells
affected cellular viability, cultures of both cell lines were
incubated with the glycolytic inhibitor 2-deoxy-D-glucose
(2DG), a modified-glucose molecule (substitution of
hydroxyl group for hydrogen at the second carbon atom)
that blocks glycolysis by inhibiting hexokinase activity, im-
pairs cancer cell growth, and induces cell death through
apoptosis [34]. Incubation of MCF7Ecadvar cells with
5 mM 2DG led to a decrease (p < 0.001) in cell viability
but not in control cells. Contrasting, the addition of
0.5 mM 2DG did not induce significant changes in
MCF7Ecadvar cell viability compared with the control,
suggesting a concentration-dependent effect of the inhibi-
tor (Fig. 5e). Finally, the association between LDHB
expression and MCF7Ecadvar cell proliferation was evalu-
ated by transfecting cells with a LDHB specific small inter-
fering RNA (siRNA). As shown in Fig. 5f, g, a decreased
expression of the transcript and protein of LDHB was
found in MCF7Ecadvar cells treated with 100 pmoL/mL
of LDHB siRNA relative to the MCF7Ecadvar cells
transfected with a scramble siRNA (siScr) used as negative
control after 72 h of treatment. This negative modu-
lation of LDHB expression resulted in a significant re-
duction (p < 0.05) of MCF7Ecadvar cell viability, when
compared with results in the MCF7Ecadvar siScr
treated cells (Fig. 5h).
E-cadherin variant and LDHB mRNA expression analysis in
tumor tissue samples from BC patients
To translate the results obtained with the MCF7Ecad-
var cellular model to the clinic, 21 breast tumor tissues
from women who underwent biopsy and/or surgery for
BC management before receiving radiotherapy or
chemotherapy were analyzed. The histological and mo-
lecular characteristics of the samples are detailed in
Additional file 6: Table S1.
Tissues were processed for total RNA extraction and
the E-cadherin variant and LDHB transcripts expression
Table 3 Description of the connection networks generated from the proteins identified as differentially expressed between
MCF7Ecadvar and MCF7pcDNA3 cells. Results obtained with the IPA tool
Network Molecules in the network Score Molecules
involved
Top diseases and functions
1 ACTA2, ACTB, AIP, C8orf44-SGK3, CRABP2, ESR1, GLIPR2, GORASP2, GP9,
GP1BA, GPI, GRB2, HIST1H2BC, HNRNPH1, HSD17B4, HSP90AA1,
HSP90AB1, HSPA9, HSPA1A, HSPA1B, IRS4, LMNB1, LMNA, NISCH,
PIK3R1, PDIA3, REV1, RPS2, SLC6A4, STIP1, TUBA1B, VCP, VIM, YWHAQ,
YWHAZ
31 16 Connective tissue disorders, developmental
disorder, hematological disease
2 AGTR1, ALDOA, APRT, AXL, AZGP1, SRC, CCND1, CLIC1, CTNNB1, EEF2,
EGFR, EGLN1, ERBB2, ERP29, FBP1, FGF7, HIF1A, HNRNPF, HNRNPH1,
HPRT1, KDM4B, LDHB, LMNA, LOXL2, MAPK1, MMP7, NCOA3, OGT,
PRDX2, PRDX6, PSMA6, PSMB3, SMARCA4, WIPF1, YWHAZ
31 16 Cardiovascular system development and
function, organismal development, cancer
3 AKR1B1, AKT1, ANXA4, APP, ATP13A2, BAG6, BCL2, BIRC3, CARM1,
CDKN1A, CLCA2, CSE1L, CST3, CTSD, CUL4B, ESRRG, G6PD, IDE, LBR, ME1,
MEMO1, MYC, NME1, NME2, PGAM1, PKG, PRL, S100A11, SMYD3, SOD1,
SRSF3, STRAP, TP53, TPI1, UBA1
19 11 Cellular development, cellular growth and
proliferation, free radical scavenging
4 GPD2, TNF 2 1 Molecular transport, nucleic acid
metabolism, small molecule biochemistry
List of the networks ordered in a descending form according to the score assigned to each of them. The symbol of molecules involved in each of the four
networks, the number of molecules among the 50 identified with differential expression levels between MCF7Ecadvar and MCF7pcDNA that were part of each
network (in bold in the second column), as well as top diseases and functions associated to each one, are also indicated in the table.
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levels were evaluated by quantitative real-time PCR. As
a result, detectable amounts of both mRNAs were
registered in the 21 breast tumors analyzed (Fig. 6a and
Additional file 7: Table S2), although expression levels of
each transcript differed among tumors.
Samples were numbered and organized in ascending
order according to the 2-ΔCt values obtained for the
E-cadherin variant transcript, which ranged from
0.000078 to 0.008669. For the LDHB mRNA, 0.011010
was the lowest 2-ΔCt value registered and 0.384302 the
highest. Using the median value of E-cadherin variant
and LDHB transcripts levels (0.000353 and 0.1073, re-
spectively) as cutoff values to group samples in “low ex-
pression” or “high expression” for each molecule, a 2 × 2
contingency table was made and the Fisher’s exact test
was applied. This analysis revealed a significant associ-
ation (odds ratio 0.06, confidence interval 0.01–0.40, p <
0.0089) between the expression levels of the E-cadherin
splice variant and LDHB transcripts. As shown in Fig. 6b,
80% of the breast tumor samples with low E-cadherin
Fig. 2 Graphical representation of the connection networks generated from the 50 proteins identified. Results obtained with IPA. In networks a 1,
b 2, c 3, and d 4, the symbols of the proteins that are part of the list of the 50 identified by 2D-DIGE and MS have a specific color, whereas the
ones incorporated by the IPA program as connectors are indicated in white. The function of each of the molecules is also represented by a
specific form. For example, in network 1, the NISCH symbol corresponds to cytokine or growth factor, REV1 to enzyme, estrogen receptor to
group or complex, PDIA3 to peptidase, AIP to transcription factor, CRABP2 to transporter, TUBA1B to another. In network 3, the symbol assigned
to CLCA2 means ionic channel, the one of AKT1 corresponds to kinase, ESRRG to ligand dependent on nuclear receptor, and PGAM1 to phosphatase.
Considering the type of connection, the full line indicates direct interaction between two molecules and the dotted line refers to an indirect type of
interaction; the direction of the arrows indicates the direction of functionality. The numbers in parentheses located over each connector indicate the
amount of scientific works that corroborate the association between these two molecules and the letters specify the type of union through which
they interact, such as A: activation, E: expression (includes metabolism and synthesis of chemicals), L: proteolysis (includes degradation of chemicals),
LO: location, M: biochemical modification, P: phosphorylation/dephosphorylation, PD: protein-DNA binding, PP: protein-protein binding, PR: protein-
RNA binding, RB: regulation of the union, T: transcription
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variant mRNA expression showed low levels of LDHB
mRNA, while 81.82% of the samples with high
E-cadherin variant expression levels presented high
LDHB mRNA expression.
Finally, taking into account that an increased expres-
sion of LDHB has been associated with a high cellular
viability and proliferation in previous reports [28, 29],
and considering that this behavior was also observed in
the MCF7Ecadvar cellular model (Fig. 5h), LDHB mRNA
levels were compared in the 21 breast tumor tissues
grouped according to the Ki-67 labeling index (samples
with Ki-67 < 20% and samples with Ki-67 ≥ 20%). The im-
munohistochemical analysis of Ki-67 is regularly utilized
to evaluate tumor cell proliferation, and is considered a
prognostic and predictive marker in BC [35]. As result of
this analysis, breast tumor tissues from the Ki-67 ≥ 20%
group showed higher LDHB transcript expression levels
than those from the Ki-67 < 20% group.
Discussion
In the mammary gland, E-cadherin is one of the main cellu-
lar adhesion molecules required for morphogenesis and
maintenance of the epithelial structure as well as for epithe-
lial cell survival [36]. BC is a complex disease that involves
cell dedifferentiation and proliferation of the mammary epi-
thelium, leading to tissue disorganization. Deregulation of
E-cadherin expression has been associated with BC pro-
gression and aggressiveness, and the underlying mecha-
nisms involved in E-cadherin expression changes have been
extensively studied [37, 38]. Dr. Vazquez-Levin’s group
identified a novel human E-cadherin splice variant tran-
script that differs from the E-cadherin wt mRNA in 34 bp
deleted in exon 14. Stable transfection of the variant tran-
script in MCF-7 cells showed a detrimental effect over the
E-cadherin wt expression, and additional molecular
changes characteristic of the EMT process and of an ag-
gressive cellular behavior [12]. Based on this background
information, a global protein analysis was carried out using
the 2D-DIGE and MS technologies to unleash the mole-
cules and mechanisms of the cellular alterations observed
associated with the overexpression of the E-cadherin vari-
ant in MCF-7 cells.
In the 2D-DIGE technique, protein mixtures of test and
control samples are obtained, labeled with different fluor-
escent dyes, mixed, and subjected to 2D-electrophoresis,
by which protein components are resolved based on their
isoelectric point and apparent molecular weight. The in-
clusion of an internal standard containing all the proteins
of the samples under study reduces gel-to-gel variations,
allows for individual experiments normalization, and con-
fers a high sensitivity and reproducibility for differential
quantitative analysis of protein expression between experi-
mental conditions [39]. Despite having some limitations,
such as under-representation of hydrophobic, membrane,
and low abundance proteins, and the difficulty to resolve
proteins with extreme isoelectric points or with very high
or low molecular weight, the comparative 2D-DIGE
method has been applied in biological and biomedical re-
search areas to discover novel biomarkers, improve diag-
nostics and prognostics, and for therapy-monitoring. The
potential of this approach lies in an accurate detection
and quantification of protein isoforms, giving information
that can be lost when using standard immunochemical as-
says and genomic analysis for protein detection [39, 40].
This electrophoresis procedure is followed by protein spot
Table 4 Diseases associated with the no common molecules between BC genes found in DisGeNET and proteins identified as
differentially expressed between MCF7Ecadvar and MCF7pcDNA3 cells. Results obtained with the DisGeNET tool
Gene Diseases
ECI1 Noninfiltrating intraductal carcinoma
PSMA6 Multiple myeloma, osteosarcoma
PMM2 Adenocarcinoma of lung (disorder)
GPD2 Prostatic neoplasms
HSPA9 Liver neoplasms, secondary malignant neoplasms of liver, liver and intrahepatic biliary tract carcinoma, renal cell carcinoma, leukemia,
myeloid leukemia, colorectal carcinoma, colon carcinoma, prostate carcinoma, carcinoma of lung, stomach carcinoma, central
neuroblastoma, medullary carcinoma of thyroid, adenocarcinoma, carcinogenesis, neoplasm metastasis, recurrent tumor
HNRNPF Colorectal neoplasms, glioma, colon carcinoma
EML2 Melanoma, pancreatic carcinoma, Lewis lung malignant neoplasm of pancreas, carcinoma, tumor-associated vasculature
GDI2 Squamous cell carcinoma of esophagus
PDIA3 Liver carcinoma, stomach neoplasms, prostate carcinoma, squamous cell carcinoma, leukemia myelocytic acute, ovarian carcinoma,
epithelial ovarian carcinoma, secondary malignant neoplasm of lymph node, malignant neoplasm of larynx, melanoma, cervical
adenocarcinoma, secondary malignant neoplasm of lung, adenocarcinoma, carcinogenesis
UBA1 Squamous cell carcinoma, neoplasm metastasis
List of the 11 genes from the 50 that coded for the proteins found with different expression levels between MCF7Ecadvar and MCF7pcDNA3 for which no
association was found with the 36 DisGeNET terms that included the words “Breast” or “Mammary,” and “Carcinoma,” “Cancer,” “Neoplasms,” or “Tumorigenesis.”
The gene symbol and the diseases in which each of them has been reported altered are indicated. The PSMB3 gene was not found in DisGeNET
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digestion and MS analysis, allowing peptide identification
with high specificity and sensitivity. The 2D-DIGE tech-
nique coupled to MS protein identification was previously
applied by members of the team [41], as well as by others,
for the characterization of the global proteome of diverse
experimental models. In particular, this approach was used
for the assessing of EMT protein profiles [42–45]. In this
regard, Vergara and collaborators [46] carried out a stable
knockdown of E-cadherin wt expression in MCF-7 cells by
transfecting with an shRNA, and changes in the proteomic
signature were evaluated using a 2D-gel electrophoresis
and MS approach, also observing changes in the expression
of proteins involved in carbohydrate metabolism, such as
PGAM1, also identified in this study, but with the opposite
trend.
The proteomic study done on MCF7Ecadvar and
MCF7pcDNA3 cells led to the identification of 50 pro-
teins depicting a significant differential expression level
between cell lines, which are involved in several signal-
ing pathways and participate in the regulation of a var-
iety of important cellular processes. In particular, 29 of
the 50 proteins identified were associated with cell
Fig. 3 Transcripts expression analysis of the ten most upregulated molecules in MCF7Ecadvar cells relative to MCF7pcDNA3. Quantitative real-time
PCR of a LDHB, AKR1B1, VIM, PDIA3, LMNA; b EEF2, HSP90AB1, YWHAQ, PDIA6; and c UBA1 in MCF7pcDNA3 and MCF7Ecadvar cells. The relative
expression was calculated as described in the “Materials and Methods” section, using GAPDH as the endogenous gene and the MCF7pcDNA3 cell line
as reference. *p < 0.05, **p < 0.01, ns not significant
Rosso et al. Cancer & Metabolism             (2019) 7:5 Page 13 of 23
metabolism, and the glycolysis and gluconeogenesis
metabolic pathways were listed as the most altered in
the MCF7Ecadvar cellular model. Other processes cate-
gorized as response to stimulus, localization and
organization of cellular components, biological regula-
tion and development, were also listed. Among the 50
proteins, there were found enzymes (LDHB, ALDR,
APT, TERA, HPRT, UBA1, G6PD, ACPH, NDKB, 6PGL,
F16P1, G6PI, PGAM1, ECI1, ALDOA, MAOX, GGCT,
PMM2, GPDM, TPIS, SODC, PRDX2, and PRDX6), pro-
teases (CATD, PSB3, and PSA6), binding (ANXA4 and
EMAL2) and transport (RABP2 and CLIC1) molecules,
chaperones (HS90A, HS90B, HS71A, HS71B, GRP75,
PDIA3, PDIA6, ERP29), structural molecules (ACTB,
ACTA, VIME and LMNA), adapter/regulatory molecules
(1433Z, 1433 T, GRB2, GDIB and EF2), splicing
(HNRH1 and HNRPF), and differentiation (S10AB) fac-
tors. Transcript expression analysis showed the same
trend of change for 11 (LDHB, AKRIB1, VIM, PDIA3,
LMNA, CRABP2, YWHAZ, G6PD, HSP90AA1, CTSD,
and ANXA4) of the 20 molecules evaluated in MCF7E-
cadvar compared with MCF7pcDNA3 cells. Interestingly,
the specific knockdown of E-cadherin wt was also associ-
ated with expression changes in a significant number of
metabolic proteins and the catalytic activity was one of
the most altered molecular function [46], suggesting that
some of the molecular changes triggered by
E-cadherin variant mRNA overexpression in MCF-7
could be associated with its role as a negative
E-cadherin wt modulator. Part of the expression
changes recorded for the molecules differentially
expressed in the MCF7Ecadvar cell line were reported
in samples from patients with different cancer types,
in particular with BC. In some cases, these changes
have also been associated with an aggressive tumor
phenotype and a worse patient prognosis.
Fig. 4 Transcripts expression analysis of the ten most downregulated molecules in MCF7Ecadvar cells relative to MCF7pcDNA3. Quantitative real-
time PCR of a CRABP2, YWHAZ, G6PD, HSP90AA1, CTSD, ANXA4; b TPI1, PRDX2, S100A11; and c GGCT in MCF7pcDNA3 and MCF7Ecadvar cells.
The relative expression was calculated as described in the “Materials and Methods” section, using GAPDH as the endogenous gene and
the MCF7pcDNA3 cell line as reference. *p < 0.05, **p < 0.01, ns not significant
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In the last decade, it was demonstrated that tumor cells
exhibit an altered expression of different metabolic en-
zymes and metabolite transporters to increase the
generation of energy necessary for a high proliferation and
migration, as well as for survival and invasion [47]. Gly-
colysis is a critical catabolic process through which a
Fig. 5 Expression analysis of LDHB in MCF7Ecadvar and MCF7pcDNA3 cells. a Western immunoblotting of the 35 kDa LDHB form in total protein
extracts of MCF7pcDNA3 and MCF7Ecadvar cells. The immunodetection of β-tubulin (55 kDa) was used as loaded control. b Immunofluorescence
analysis of LDHB (× 200 magnification, scale bar 50 μm) coupled to nuclear staining with dye Hoechst 33342 in MCF7pcDNA3 and MCF7Ecadvar
cells. Negative controls were included for both cell lines. Quantification of the LDHB specific signal was also done and indicated in the bar graph.
c, d Determination of c glucose and d lactate concentrations (mg/dL) in the 72-h-conditioned media of MCF7Ecadvar and MCF7pcDNA3 culture
cells. Measurements were done with a Cobas 8000 equipment. e Cellular viability analysis of MCF7pcDNA3 and MCF7Ecadvar culture cells after
24 h treatment with 0, 0.5, or 5 mM of the 2DG glycolytic inhibitor. f Quantitative analysis of LDHB by real-time PCR in MCF7Ecadvar siScr and
MCF7Ecadvar siLDHB cells. The relative expression was calculated as described in the “Materials and Methods” section, using GAPDH as the
endogenous gene and the MCF7Ecadvar siScr cell line as reference. g Western immunoblotting of the 35 kDa LDHB form in total protein extracts
of MCF7Ecadvar siScr and MCF7Ecadvar siLDHB cells. The immunodetection of β-tubulin (55 kDa) was used as loaded control. Quantification of
the LDHB specific signal was also done and indicated in the bar graph. h Cellular viability analysis of MCF7Ecadvar siScr and MCF7Ecadvar siLDHB
culture cells after 72 h treatment with 100 pmoL/mL of a LDHB specific siRNA. *p < 0.05, ***p < 0.001
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glucose molecule is cleaved to produce two molecules of
pyruvate, two molecules of adenosine triphosphate (ATP),
and two of NADH. In normal cells, the fate of pyruvate
depends, to a large extent, on oxygen availability. In its
presence, pyruvate is oxidized to acetyl coenzyme A (acet-
il-CoA), which is then completely oxidized to carbon di-
oxide and water in the tricarboxylic acid cycle, generating
3 NADH and 1 flavin adenine dinucleotide hydroquinone
form (FADH2). As a result, the reducing power produced
through these processes is used to yield large amounts of
energy in the form of ATP through the mitochondrial oxi-
dative phosphorylation system. In contrast, in the absence
of oxygen, glycolysis is decoupled from oxidative phos-
phorylation and pyruvate is transformed into lactate
through the anaerobic glycolysis metabolic pathway, be-
coming the primary source of ATP production.
Almost 100 years ago, Warburg and collaborators re-
ported that aerobic glycolysis and lactate generation
were increased in tumor cells, allowing a faster produc-
tion of energy than through the oxidative phosphoryl-
ation carried out by normal cells [48]. Among the ten
proteins upregulated in the MCF7Ecadvar cellular
model, LDHB showed the highest positive fold change.
Since LDHB catalyzes interconversion of pyruvate (the
Fig. 6 Transcripts expression analysis of E-cadherin variant and LDHB in human breast tumor samples. a Quantitative expression analysis of
E-cadherin variant and LDHB by real time PCR in 21 human breast tumor tissues. Samples were numbered and ordered in an ascending form
according with the 2-ΔCt values obtained for the E-cadherin variant mRNA. b Transcripts levels association analysis of E-cadherin variant with
LDHB in 21 human breast tumor tissues. The expression levels of both markers were indicated as low or high using the median value of
E-cadherin variant and LDHB transcripts levels as cutoff values. The gray box highlights a significant association between E-cadherin variant and
LDHB overexpression using the Fisher exact test (p < 0.0089). c Analysis of the LDHB mRNA expression levels in 21 human breast tumor samples
divided in 2 groups according to their Ki-67 labeling index (Ki-67 < 20% and Ki-67≥ 20%). *p < 0.05\
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glycolysis final product) and lactate, quantification of
glucose and lactate levels in MCF7Ecadvar and
MCF7pcDNA3 conditioned media was done. These
studies revealed an increased glucose consumption and
lactate production by MCF7Ecadvar cells. Moreover, the
decrease in the expression of enzymes involved in gluco-
neogenesis (FBP1, GPI, PGAM1, ALDOA, ME1, and
TPI1) and in the pentose phosphate pathway (G6PD and
PGLS) registered in MCF7Ecadvar cells with respect to
control would contribute to the increased availability of
glucose-6-phosphate for the aerobic glycolysis over the
pathways responsible of the synthesis of glycogen, fatty
acids, and nucleic acids. An association between
E-cadherin variant and LDHB levels was also demon-
strated through the analysis of both transcripts in 21 hu-
man breast tumor samples.
To achieve the reprogramming of metabolism, tumor
cells depend on the action of specific transcription fac-
tors, such as hypoxia-inducible factor 1-alpha (HIF1A)
and MYC [49–51]. The activation of the PI3K, AKT,
mTOR, Ras, Raf, Src, and EGFR oncogenes [52, 53], as
well as the loss of tumor suppressor genes like PTEN
and TP53 [54, 55], were also demonstrated to exacer-
bate tumor cell growth and metabolism. Some of these
molecules were involved in the list of the ten canonical
pathways identified by the IPA tool as the most altered
in MCF7Ecadvar compared with MCF7pcDNA3 cells
(mTOR, PI3K, and AKT) or were included as connec-
tors into the IPA networks to link some of the prote-
omic molecules (EGFR, HIF1A, AKT1, MYC, and
TP53). Particularly, it was reported that LDHB is tar-
geted by the mTOR complexes and plays a fundamental
role in the tumorigenesis triggered by the PI3K/AKT
signaling pathway [56], all major mediators of cell sur-
vival. These findings could be related to the diminished
cellular viability found in MCF7Ecadvar cells after the
specific knockdown of LDHB expression. Moreover, the
analysis of LDHB mRNA levels in 21 human breast
tumor tissues showed that samples with Ki-67 labeling
index ≥ 20% had higher levels of the LDHB transcript
than those with a Ki-67 < 20%, reinforcing that the
overexpression of the LDHB enzyme is necessary for a
faster tumor growth [30, 31] and a more aggressive tu-
moral behavior [57, 58].
Conclusions
Taken together, results obtained from the 2D-DIGE and
MS proteomic analysis done in MCF7Ecadvar and
MCF7pcDNA3 cells revealed the complexity of the mo-
lecular effects associated with the overexpression of the
novel E-cadherin splice variant mRNA in MCF-7 cells.
While a large proportion (39 of 50) of the proteins identi-
fied as differentially expressed between both cell lines had
been previously reported in the literature associated with
BC, for some of them the available information is scarce
and sometimes contradictory. Thus, the stable transfec-
tion of the novel E-cadherin variant transcript in MCF-7
cells may represent a useful experimental model to deepen
in the knowledge of the cellular alterations associated with
the deregulation of E-cadherin wt in this complex and het-
erogeneous disease. Specifically, this is the first report that
describes the involvement of a novel E-cadherin splice
variant in triggering molecular changes related to BC pro-
gression and aggressiveness and its relationship with
LDHB expression.
Methods
Chemicals
Chemicals were of analytical or tissue culture grade and
purchased from Sigma-Aldrich (Sigma; St. Louis, MO,
USA). Molecular biology and electrophoresis reagents
were purchased from Invitrogen (Thermo Fisher Scien-
tific; Waltham, MA, USA), Qiagen (Hilden, Germany),
and Bio-Rad (Hercules, CA, USA), unless specified.
The following antibodies were used: anti E-cadherin
(610,181, mouse, monoclonal; Becton Dickinson Biosciences
[BD], San Diego, CA, USA), anti LDHB (431.1, mouse,
monoclonal; Santa Cruz Biotechnology [SCBT], Santa Cruz,
CA, USA), and anti β-tubulin (clone D66, mouse, monoclo-
nal; Sigma). For immunocytochemistry, a Cy3-labeled
anti-mouse (Sigma) IgG was used as secondary antibody.
An anti-mouse (Vector Laboratories Inc.; Burlingame, CA,
USA) IgG coupled to horseradish peroxidase was employed
as secondary antibody in Western immunoblotting assays.
In silico analysis
The following bioinformatics tools were used in this
study:
PANTHER
Comprehensive software system for classifying proteins
(and their genes) depending on the family or subfamily they
belong, the molecular function they have, the biological
process they are involved, or the way in which they partici-
pate on it. The classifications result from human data heal-
ing and sophisticated bioinformatics algorithms [59, 60].
DisGeNET
Discovery platform that integrates information on
gene-disease associations by text-mining approaches
from expert-curated databases and scientific literature.
Data is organized according to their type and level of
curation in curated (gene-disease associations from
UNIPROT and CTD human databases), predicted (CTD
mouse and rat data, RGD and MGD), literature (GAD,
LHGDN, and BeFree), and all (curated, predicted, and
literature). The gene-disease associations can be ranked
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according to a 0 to 1 DisGeNET score and are annotated
with the DisGeNET gene-disease association type ontol-
ogy. The score takes into account the number and type
of sources (i.e., level of curation and organisms), as well
as the number of publications supporting the associ-
ation. It can be accessed through the web interface [61]
or using a Cytoscape plugin [62] (see below).
Venny
Online tool to compare lists of genes or proteins by per-
forming Venn diagrams. It also allows visualization of
specific elements of each list, as well as common ele-
ments between them [63].
IPA
Web-based software application for the analysis, integra-
tion, and interpretation of data derived from omics ex-
periments. It also transforms a list of genes or gene
products into a set of networks based on the ingenuity
knowledge base, which has been abstracted into a large
network called global molecular network composed of
thousands of genes that interact with each other. The re-
lationship between two genes is called connection and
two genes are considered to be connected if there is a
path between them in the network, i.e., a set of genes
connecting one to the other. If the relationship between
genes of a list of interest is not direct, the IPA program
relates them through other neighboring genes present in
the global molecular network. In addition, IPA assigns a
score value to each network and the higher the score the
higher the degree of confidence for the connections
identified in the network [64].
Laboratory procedures
All procedures reported in this study were done follow-
ing protocols that complied with biosafety and ethical
guidelines accepted worldwide.
Tissue samples
Twenty-one tumor tissue samples from patients diagnosed
with BC of different subtypes and stages of the disease were
obtained from the Hospital Italiano of Buenos Aires and
the Instituto de Oncología Ángel H. Roffo, Buenos Aires,
Argentina. Sample collection protocols were approved by
the institutional Ethics Committees and patient informed
consents were obtained in all cases. The study was con-
ducted in accordance with the principles of the Declaration
of Helsinki. Samples were from women older than 18 years
old, who underwent biopsy and/or surgery because of BC
diagnosis. The breast tumor tissues of patients that received
radiotherapy or chemotherapy before surgery were ex-
cluded from the study.
Cell cultures
Cell lines were grown in appropriate culture conditions
as previously described [12]. Briefly, MCF-7 human BC
cells, as well as MCF7Ecadvar and MCF7pcDNA3 stably
transfected cells, were cultured in sterile culture dishes
(Nunc, Thermo Fisher Scientific) at 37 °C in a humid at-
mosphere containing 5% CO2 in air. Cells were grown in
the Dulbecco’s modified Eagle’s medium Ham’s Nutrient
Mixture F-12 (DMEM F-12; Gibco, Thermo Fisher Sci-
entific) cell culture medium, supplemented with 10%
fetal calf serum (FBS), 100 U/mL penicillin, 100 mg/mL
streptomycin, and 2 mM glutamine. Upon reaching 80%
confluence, cells were sub-cultured using a 0.25% sterile
solution of trypsin and 0.025% ethylenediaminetetraace-
tic acid (EDTA) in phosphate-buffered saline (PBS).
Proteomic analysis
Proteomic analysis was done employing 2D-DIGE tech-
nology coupled to protein identification by MS at the
Proteomics Service of the Vall d’Hebron Institute of On-
cology, Vall d’Hebron University Hospital, Barcelona,
Spain, basically as previously reported [65].
For sample preparation, triplicates of MCF7Ecadvar
and MCF7pcDNA3 cell cultures were grown in Petri
dishes (Nunc, Thermo Fisher Scientific) as described be-
fore. When cells reached 60–70% confluence, the growth
medium was replaced by medium without FBS supple-
mentation. After 24 h, cultures were collected with
5 mM EDTA, centrifuged 5 min at 200×g and stored at
− 70 °C until use.
For the proteomic analysis, cellular pellets were lysed
with 400 μL of DIGE lysis buffer (pH 8.5; 30 mM Tris,
7 M urea, 2 M thiourea, 4% CHAPS) to achieve protein
extraction. After sonication, protein extracts were puri-
fied using the 2D-CleanUp kit (GE Healthcare; Bucking-
hamshire, UK) and re-dissolved in DIGE lysis buffer.
Protein concentration was determined with the Bio-Rad
RC DC Protein Assay (Bio-Rad). Proteins were then la-
beled using the Ettan DIGE method (GE Healthcare). A
pool consisting of equal amounts of each of the samples
analyzed in this study was prepared to be used as an in-
ternal standard for quantitative comparisons. Triplicates
from MCF7Ecadvar and MCF7pcDNA3 cell cultures
were alternatively labeled with Cy3 and Cy5 cyanine
dyes to avoid possible bias by labeling efficiency, and the
internal standard was labeled with the Cy2 dye. The rec-
ommended marker/protein ratio of 400 picomoles of
marker per 50 μg of total proteins was used.
MCF7Ecadvar and MCF7pcDNA3 total protein samples
were separated in a first-dimension by the IEF technique
using the IPGphor system (GE Healthcare). The IPGphor
strips have a length of 24 cm and cover a range of 3 to 10
pH units. Isoelectrical focusing was carried out overnight
or until reaching 8000 Vh. Total proteins separation in a
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second-dimension was carried out by laying the strips on
12.5% isocratic Laemmli gels (24 × 20 cm) on an Ettan
DALTsix Electrophoresis System (GE Healthcare). Gels
were run at 20 °C at constant power (2.5 W) per gel for
30 min, followed by 17 W per gel until the bromophenol
blue tracking front reached the end of the gel. When the
run was finished, gels were scanned with the Typhoon
FLA 7000 Scanner (GE Healthcare; Cy2: 488/520 nm,
Cy3: 532/580 nm and Cy5: 633/670 nm excitation/emis-
sion wavelengths). Image analysis and statistical quantifi-
cation of relative protein abundances were performed
using Progenesis Samespots (Nonlinear Dynamics, UK)
and a DeCyder 6.0 version software (GE Healthcare). Pro-
tein spots that met a 1.5-fold change cutoff and an
ANOVA ≤ 0.005 were considered. Once detected, the
spots differentially expressed between MCF7Ecadvar and
MCF7pcDNA3 samples were excised from the gels using
the Ettan SpotPicker System (GE Healthcare). In-gel tryp-
sin digestion was performed as previously described [66]
using autolysis stabilized trypsin (Promega, Madison, WI,
USA) and tryptic digests were purified with ZipTip Pipette
Tips (EMD Millipore, Cork, Ireland). Spectra of the
protein spots selected were obtained by the matrix-
assisted laser desorption ionization-time of flight (MAL-
DI-TOF), MALDI/TOF-TOF, and liquid chromatography-
electrospray ionization-MS in tandem (LC-ESI-MS/MS)
techniques. Protein identity determination in each spot re-
covered was done through the Mascot Database Search
Program.
Transfection with LDHB siRNA
To knockdown endogenous LDHB gene expression,
250,000 MCF7Ecadvar cells per well were seeded in
6-well plates (Nunc, Thermo Fisher Scientific). After
24 h, cells were transfected with 100 pmoL/mL of a spe-
cific LDHB or a scramble (SCBT) siRNA, using Lipofec-
tamine 2000 (Thermo Fisher Scientific) and following
manufacturer’s instructions. Seventy-two hours after
transfection, cells were recovered with EDTA 5 mM to
perform LDHB mRNA and protein expression analysis.
In addition, assessment of cellular viability was done
with the CellTiter 96 AQueous Non-Radioactive Cell
Proliferation Assay (Promega; Madison, WI, USA).
Briefly, three replicates of 5000 cells were done from
both LDHB and control siRNA transfections, and cul-
tured for 5 days at 37 °C in 5%CO2 in air. Cells were
harvested and each replicate was seeded in 5-wells of a
96-well plate. Then, 20 μL of the reagent solution of
2 mL MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] and
0.1 mL PMS (phenazine methosulfate) were added to
each well and incubated for 1 h, after which absorbance
was read at 490 nm on a microtiter spectrophotometer
plate reader (Thermo Fisher Scientific). Controls without
cells were included for background estimation.
Total RNA extraction and real-time PCR procedures
Total RNA from MCF-7, MCF7pcDNA3, and MCF7E-
cadvar cell cultures, as well as from breast tumor tissue
samples, was isolated with the Trizol reagent (Thermo
Fisher Scientific) following the manufacturer’s instruc-
tions and quantified (Nanodrop, Thermo Fisher Scien-
tific). Synthesis of complementary DNA (cDNA) was
performed with oligo-dT and SuperScript™ III Reverse
Transcriptase (Thermo Fisher Scientific). Negative
controls omitting the RNA or the reverse transcriptase
enzyme were included in all cases. Standard PCR ampli-
fication protocols were carried out using the TaqI DNA
polymerase (Qiagen). Reverse transcription procedures
were verified by amplification of a glyceraldehyde
3-phosphate dehydrogenase (GAPDH) cDNA fragment.
Quantitative assessment of gene expression was done
by real-time PCR with the Bio-Rad Real Time PCR unit
using the SYBR Select Master Mix (Thermo Fisher Sci-
entific). All samples were run in triplicates and negative
controls (no template) were included in all cases.
Primers used in this study were designed using the
Primer-BLAST program (http://www.ncbi.nlm.nih.gov/
tools/primer-blast) and synthesized by Eurofins MWG
Operon (Louiswille, KY, USA).
Relative expression was calculated using GAPDH as en-
dogenous control. Expression levels of Ecadvar mRNA
were determined with primers originally designed for its
identification [12]: forward: 5′-GACCAAGTGACCAC
CTTAGA-3′, reverse: 5′GACCACCGCTCTCTTAGC3 ′.
When indicated, the MCF7pcDNA3 cell line or the
MCF7Ecadvar cells transfected with the scramble siRNA
(MCF7Ecadvar siScr) were used as references as specific-
ally indicated. The calculation used to describe these rela-
tions was 2-ΔΔCt, where ΔΔCt = [ΔCt test sample − ΔCt
reference sample] and ΔCt = [Ct gene under study − Ct
endogenous gene].
One-dimension protein electrophoresis and Western
immunoblotting
For total protein extraction, cell cultures were washed
twice at 4 °C with PBS (pH 7.4) supplemented with 2 mM
CaCl2 and placed at − 20 °C until processing. Cells were
then resuspended in Laemmli sample buffer, boiled for
5 min, and sonicated three times for 30 s at maximum
power (Sonifier Cell Disruptor, model W-140; Heat
Systems-Ultrasonics Inc., Plainview, NY, USA). Cell lysates
were centrifuged 30 min at 10,000×g at 4 °C to eliminate
cellular debris and stored at − 70 °C until used. Protein
concentration was determined by the Bradford Protein
Assay (Bio-Rad). Protein mixtures of cellular lysates
were supplemented with 5% β-mercaptoethanol final
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concentration, boiled for 10 min, and subjected to
SDS-PAGE in 8 or 10% polyacrylamide gels. Molecular
weight standards (Bio-Rad) were included in all runs. After
Western immunoblotting, a replica of protein patterns was
obtained on nitrocellulose membranes (Hybond-ECL; GE
Healthcare) using standard procedures. Membranes were
placed for 1 h at room temperature with PBS containing
0.02% Tween-20 and 5% skimmed milk powder (blocking
buffer), followed by overnight incubation at 4 °C with the
specific primary antibody diluted in blocking buffer. Blots
were washed, placed for 1 h at room temperature with the
secondary antibody in blocking buffer, and developed with
enhanced chemiluminescence (ECL kit; GE Healthcare),
following the procedure suggested by the manufacturer.
Replicates of three experiments were obtained and a densi-
tometric analysis of the bands was performed using the
ImageJ software (Wright Cell Imaging Facility, UHNR, CA,
USA), when indicated. A representative image of each ex-
periment is shown.
Fluorescence immunocytochemistry
MCF7Ecadvar and MCF7pcDNA3 cells grown on glass
coverslips until 80% confluence were fixed with 4% (v/v)
paraformaldehyde in PBS for 10 min and permeabilized
in PBS supplemented with 0.2% (v/v) Triton X-100. For
fluorescence immunocytochemistry, non-specific bind-
ing sites were blocked with 4% (w/v) bovine serum albu-
min in PBS followed by overnight incubation at 4 °C
with an anti LDHB antibody (2 μg/mL) or mouse IgG
(control). After several washes, cells were incubated with
purified secondary antibody coupled to Cy3-fluorophor
for an additional hour. Nuclear staining was done by in-
cubation with Hoechst 33342 (Sigma). Coverslips were
mounted with Vectashield anti-fade solution (Vector).
Images were acquired with a Nikon laser confocal
microscope C1 (Nikon, Tokyo, Japan; excitation lines:
488 nm and 544 nm, emission filters: 515–530 nm and
570-LP nm) using a × 20 objective and were analyzed
using the ImageJ software when specified.
Assessment of glucose and lactate concentrations
Conditioned media of MCF7Ecadvar and MCF7pcDNA3
cell cultures were collected and subjected to assessment of
glucose and lactate concentrations (mg/dL). Briefly, cells
were grown to 70% confluence as previously described.
Cultures were washed twice with PBS and media was re-
placed by fresh medium supplemented with 2% fetal bo-
vine serum. After 72 h incubation, the media were
collected in sterility, centrifuged at 200×g for 10 min to re-
move cellular debris and used. The glucose and lactate
concentrations were determined at the Dr. Enrique Rossi
Diagnostic Centre, Buenos Aires, Argentina, using a
Cobas 8000 equipment (Roche Diagnostics, Basel,
Switzerland).
Cell treatment with 2DG
To evaluate the effect of 2DG (Sigma D6134) upon
growth of MCF7Ecadvar and control cell cultures, 5000
cells were seeded in triplicates in a 96-well plate in
DMEM medium freed of phenol red containing 5% FBS.
After 18–20 h, culture medium was replaced by the
same medium containing 2DG at 0.5 mM or 5 mM final
concentrations and incubated for 96 h at 37 °C in 5%
CO2 in air. Cells incubated in the absence of 2DG were
also included and considered as the control condition.
At the end of the incubation, cell viability was evaluated
with the CellTiter 96 AQueous Non-Radioactive Cell
Proliferation Assay, adding the reagent and reading the
absorbance after 4-h incubation as described above.
Statistical analysis
All experiments were run in triplicates. Data are presented
as the mean ± standard error of the mean (SEM). Evalua-
tions done on MCF7Ecadvar and MCF7pcDNA3 cells
were carried out using the Mann-Whitney test or the
two-way ANOVA test followed by Bonferroni’s post-hoc
test analysis. Studies performed on human samples were
done using the Fisher’s exact test or the Mann-Whitney
test, as detailed. A p < 0.05 was considered significant for
each comparison. Statistical analyses and graphs were per-
formed using the GraphPad Prism version 5.01 software
(GraphPad Software, La Jolla, CA, USA).
Additional files
Additional file 1: Figure S1. E-cadherin protein expression analysis in
MCF7Ecadvar and MCF7pcDNA3 cells. Western immunoblotting of the
120 kDa E-cadherin wild type (E-cadherin wt) full length form in total
protein extracts obtained from 3 MCF7pcDNA3 (1 to 3, 10 μg per
lane) and 3 MCF7Ecadvar (4 to 6, 20 μg per lane) cell cultures. The
immunodetection of β-tubulin (55 kDa) was used as loaded control.
(TIF 2449 kb)
Additional file 2: Figure S2. Cellular components and protein classes
associated with the 50 proteins identified. Results obtained with
PANTHER. (A) Column graph bar in which the percentage (%) of each
cellular component was determined from the number of proteins
included in each category (cell part 52.5%, organelle 26.1%, macromolecular
complex 10.9%, extracellular region 6.5% and membrane 4.3%). A table
including the number and symbol of the proteins involved in each protein
class category is also shown. (B) Column graph bar in which the percentage
(%) of each protein class was determined from the number of proteins
included in each category (oxidoreductase 19.6%; hydrolase 15.2%;
isomerase 10.9%; chaperone 8.7%; transferase 8.7%; cytoskeletal
protein 6.5%; nucleic acid binding 6.5%; ligase, enzyme modulator
4.3% and lyase, 4.3% each; calcium-binding protein, membrane-traffic
protein signaling molecule, transfer/carrier protein and transporter,
2.2% each). A table including the number and symbol of the proteins
involved in each protein class category is also shown. (TIF 2499 kb)
Additional file 3: Figure S3. Genes associated with human BC. Results
obtained with DisGeNET. List of the 5261 human genes that emerged
from the 36 terms (“Breast Carcinoma”, “Female Breast Carcinoma”, “Stage
0 Breast Carcinoma”, “Stage IIIA Breast Carcinoma”, “Stage IIIB Breast
Carcinoma”, “Invasive Ductal Breast Carcinoma”, “Invasive Lobular Breast
Carcinoma”, “Secretory Breast Carcinoma”, “Inflammatory Breast
Carcinoma”, “Adenoid Cystic Breast Carcinoma”, “Apocrine Breast
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Carcinoma”, “Invasive Apocrine Breast Carcinoma”, “Intermediate Grade
Ductal Breast Carcinoma In Situ”, “Breast Carcinoma Metastatic in the
Skin”, “Breast Cancer 3”, “Breast Cancer Stage II”, “Stage III Breast Cancer
AJCC v6”, “Breast Cancer Recurrent”, “Bilateral Breast Cancer”, “Breast
Cancer and Pregnancy”, “Breast Cancer, Familial”, “Breast Cancer (non-
specific) Premenopausal”, “Contralateral Breast Cancer”, “Unilateral Breast
Neoplasms”, “Malignant Neoplasm of Breast”, “Malignant Neoplasm of
Female Breast”, “Malignant Neoplasm of Breast Stage I”, “Malignant
Neoplasm of Breast Staging”, “Secondary Malignant Neoplasm of Female
Breast”, “Triple Negative Breast Neoplasms”, “Mammary Carcinoma,
Human”, “Mammary Ductal Carcinoma”, “Mammary Neoplasms”,
“Mammary Neoplasms, Human”, “Mammary Neoplasms, Experimental”
and “Mammary Tumorigenesis”) found in DisGeNET containing the words
“Breast” or “Mammary”, and “Carcinoma”, “Cancer”, “Neoplasms” or
“Tumorigenesis”. The 39 genes in common with those that code for the
50 proteins identified by 2D-DIGE and MS as differentially expressed
between the MCF7Ecadvar and MCF7pcDNA3 cell lines are highlighted.
(PDF 168 kb)
Additional file 4: Figure S4. Specific primers for the top-10 upregulated
and downregulated molecules among the 50 identified. List of the
primers used for the evaluation of the expression levels of the mRNAs
that code for the 10 most (A) upregulated and (B) downregulated
proteins identified with differential expression levels between
MCF7Ecadvar and MCF7pcDNA3 cells by 2D-DIGE and MS. The sequence
of the forward and reverse primers, as well as the size of each amplified
product, are indicated. (TIF 2455 kb)
Additional file 5: Figure S5. Transcripts expression analysis of MCT1
and MCT4 in MCF7Ecadvar and MCF7pcDNA3 cells. Quantitative
expression analysis of (A) MCT1 and (B) MCT4 lactate transporters by real
time PCR in MCF7pcDNA3 and MCF7Ecadvar cells. The relative expression
was calculated as described in the Materials and Methods section, using
GAPDH as the endogenous gene and the MCF7pcDNA3 cell line as
reference. *p < 0.05. (TIF 4993 kb)
Additional file 6: Table S1. Histological and molecular characteristics of
breast tumor tissue samples. Description table in which the histological
type and grade, the presence or absence of metastasis, the expression
pattern of ER, PR and HER2, the percentage (%) of Ki-67 staining,
as well as the molecular subtype of 21 breast tumor tissues, are
detailed. (DOCX 17 kb)
Additional file 7: Table S2. Transcripts expression analysis of E-cadherin
variant and LDHB in human breast tumor samples. Quantitative expression
analysis of E-cadherin variant and LDHB by real time PCR in 21 human
breast tumor tissues. Samples were numbered and ordered in an ascending
form according with the 2-ΔCt values obtained for the E-cadherin variant
mRNA. (DOCX 15 kb)
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